The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world effectiveness of post-T-DM1 treatments in HER2-positive metastatic breast cancer: KBCSG-TR1917 observational study.
 
Norikazu Masuda
Leadership - Japan Breast Cancer Research Group
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly Japan; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Tetsuhiro Yoshinami
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - Chugai Pharma; Novartis
 
Hiroyuki Yasojima
No Relationships to Disclose
 
Nobuyoshi Kittaka
No Relationships to Disclose
 
Masato Takahashi
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Lilly; Nippon Kayaku; Pfizer
Research Funding - Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Kayaku (Inst); Taiho Pharmaceutical (Inst)
 
Shoichiro Ohtani
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Pfizer
 
Seung Jin Kim
Honoraria - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Hiroyuki Kurakami
No Relationships to Disclose
 
Naoko Yamamoto
Employment - Bayer Yakuhin (I)
Stock and Other Ownership Interests - Bayer Yakuhin (I)
 
Tomomi Yamada
No Relationships to Disclose
 
Takehiko Takata
Employment - Daiichi Sankyo
 
Takahiro Nakayama
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Taiho Pharmaceutical; Takeda